[A randomized study of subconjonctival bevacizumab (Avastin®) injection for corneal neovascularization].

Purpose: The goal of this phase III, comparative, multicentric, randomized, double-blinded clinical trial was to investigate the superiority of subconjunctival bevacizumab injections versus placebo in the treatment of corneal neovascularization.

Patients And Methods: We included 38 eyes (38 patients) with corneal neovascularization. Twenty patients received bevacizumab and 18 placebos.